Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00841191 · ClinicalTrials.gov registry record · Phase 1
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
A Phase 1 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT00841191 is a Phase 1 study that has completed, run by Centocor. The registered enrollment target is 84 participants.
The verdict
NCT00841191, a Phase 1 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in participants with solid malignant (cancerous) tumors (a mass in a specific area) and to estimate the clinical benefit of siltuximab monotherapy in participants with ovarian cancer and with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant tumors.
Interventions
- DRUG CNTO 328; Anti-interleukin-6 monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00841191
The ClinicalTrials.gov registry entry for NCT00841191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CNTO 328; Anti-interleukin-6 monoclonal antibody is the first listed.
NCT00841191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00841191 about?
NCT00841191 is a clinical study titled "A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors". The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in participants with solid malignant (cancerous) tumors (a mass in a specific area) and to estimate the clinical benefit of siltuximab monotherapy in participants with ovarian cancer and with Kirsten rat sarcom...
What is the current status of trial NCT00841191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2009-03. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00841191?
The interventions under investigation include: CNTO 328; Anti-interleukin-6 monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT00841191?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.